Albert Bourla, who has been with Pfizer for more than 25 years, is currently the company’s chief executive officer (CEO) and chairman. Before assuming the CEO position in January 2019, he was chief operating officer (COO) starting in January 2018. From February 2016 to December 2018, Bourla was group president of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business. He was president and general manager of the company’s Established Products business from 2010 to 2013. Bourla served in a number of other roles from 1993, when he joined the company, to 2010. Yes, Pfizer pays a regular quarterly cash dividend of $0.39 per share.

  1. However, investors can’t ignore the big hole that the slumping demand for Comirnaty and Paxlovid is causing.
  2. It reflects little to no year-over-year growth from Pfizer, which is on track to generate revenue of $58 billion to $61 billion in 2023.
  3. For those with a long-term perspective who are seeking juicy dividends, however, buying Pfizer after today’s sell-off could be a smart move.

Investors of record on Friday, January 26th will be paid a dividend of $0.42 per share on Friday, March 1st. This represents a $1.68 dividend on an annualized basis and a yield of 6.14%. This is an increase from the stock’s previous quarterly dividend of $0.41. Pfizer continues to experience a steep decline in sales for COVID-19 vaccine Comirnaty and antiviral drug Paxlovid. The company expects combined sales for the two products in 2024 will total only $8 billion, down from a projected $12.5 billion this year.

It was the first mass producer of the “miracle drug” penicillin in the 1940s and was generating more than a billion dollars in sales by the early 1970s. Pfizer has become one of the biggest pharmaceutical companies in the world, with a market capitalization of $251.3 billion as of Nov. 3, 2021. 17 equities research analysts have issued 1 year price targets for Pfizer’s stock.

2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public. The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each.

Other key products outside of the coronavirus portfolio are heading for revenue declines too, due to patent expirations. Cancer drug Ibrance and blood thinner Eliquis — both set to lose exclusivity later this decade — delivered more than $5 billion and $6 billion in revenue, respectively, in 2022. But this pharmaceutical giant hasn’t turned the final page in its growth story; instead, it’s taken steps to renew its portfolio of products and boost revenue. Pfizer (PFE -1.08%) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine.

That product, Comirnaty, and the treatment Paxlovid, released later, helped Pfizer’s revenue reach a record level of $100 billion in 2022; the two products made up more than half of that. And we shouldn’t forget that Pfizer also pays an annual dividend of $1.64 per share, which currently yields over 5.4% — far surpassing the yield of the S&P 500 index. This means you can count on Pfizer for passive income even during times of share-price weakness.

Does Pfizer pay a dividend?

The Motley Fool has positions in and recommends Pfizer and Seagen. As of Aug. 9, 2021, Pfizer had 5,606,688,356 shares of voting common stock outstanding. On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization (EUA) from the U.S. The vaccine was approved for emergency use for individuals 16 years of age and older. On May 10, 2021, the FDA expanded the EUA for the Pfizer-BioNTech vaccine to include adolescents ages 12–15. © 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Pfizer’s stock was trading at $28.79 at the beginning of 2024. Since then, PFE shares have decreased by 5.0% and is now trading at $27.36. Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, xabcd pattern indicator suite for ninjatrader 8 and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine.

The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer reported adjusted net income attributable to its common shareholders of $25.2 billion on $81.3 billion in annual revenue in its 2021 fiscal year (FY). Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list.

Where Will Pfizer Be in 10 Years?

Recently, Pfizer cut this year’s revenue guidance to a range of $58 billion to $61 billion, due to decreased demand for coronavirus products. First, investors worried about sales of Pfizer’s coronavirus products in a post-pandemic world. And second, some of Pfizer’s older blockbusters face patent expirations in the coming years. All of this means revenue is set to fall, at least in the near term.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Now, let’s get back to our question about where Pfizer will be 10 years from now. But before we start worrying too much about Pfizer’s future, let’s consider what the company is doing now to reignite growth down the road. The company has been preparing for this moment of patent expirations by readying new candidates to ensure future growth. As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children.

Since a pandemic is an uncommon situation, we shouldn’t use Pfizer’s revenue levels during peak pandemic times as a comparison point. Instead, using 2019 revenue of $51 billion offers a more accurate comparison. And from there, we can see potential for significant progress by 2030, with possible revenue growth of about 65%. I would expect momentum to continue through the early 2030s as pipeline programs reach the finish line, adding to revenue.

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise. On Oct. 29, 2021, the FDA extended the EUA for the vaccine to include children ages 5–11.

Leave a Reply

Your email address will not be published. Required fields are marked *